Hologic, Inc. Hologic, Inc.

Hologic, Inc.

HOLX

Rangering i aksjer #1329
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Aksjekurs
$76.01
Sist synkronisert: 2026-04-07
Markedsverdi
$16.97B
Endring (1 dag)
0.00%
Endring (1 år)
8.82%
Land
US
Handel Hologic, Inc. (HOLX)

Kategori

Healthcare
Driftsmargin for Hologic, Inc. (HOLX)
Driftsmargin per October 2026 TTM: 23.34%
Ifølge Hologic, Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 23.34%. Ved slutten av 2024 hadde selskapet en driftsmargin på 24.07%.
Historikk for driftsmargin for Hologic, Inc. fra 2000 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
2026 (TTM) 23.34% 33.98%
2025 17.42% -27.63%
2024 24.07% 45.17%
2023 16.58% -50.84%
2022 33.73% -23.41%
2021 44.04% 50.51%
2020 29.26% 633.33%
2019 3.99% -153.99%
2018 -7.39% -116.50%
2017 44.80% 131.29%
2016 19.37% 15.16%
2015 16.82% 52.22%
2014 11.05% -130.39%
2013 -36.36% -740.14%
2012 5.68% -72.86%
2011 20.93% 403.13%
2010 4.16% -103.38%
2009 -123.18% 943.90%
2008 -11.80% -158.97%
2007 20.01% 83.92%
2006 10.88% -4.06%
2005 11.34% 106.18%
2004 5.50% 271.62%
2003 1.48% 30.97%
2002 1.13% -110.72%
2001 -10.54% -63.88%
2000 -29.18% 0.00%
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
31.28% -98.66%
US
12.36% -99.47%
FR
0.00% -
JP
9.83% -99.58%
US
0.00% -
CH
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.